Vyome Holdings, Inc. (HIND)

NASDAQ: HIND · Real-Time Price · USD
5.86
-0.35 (-5.64%)
At close: Oct 8, 2025, 4:00 PM EDT
5.87
+0.01 (0.17%)
After-hours: Oct 8, 2025, 4:30 PM EDT
-5.64%
Market Cap32.61M
Revenue (ttm)394,490
Net Income (ttm)-1.46M
Shares Out 5.57M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume118,256
Open6.16
Previous Close6.21
Day's Range5.71 - 6.17
52-Week Range5.04 - 720.00
Betan/a
AnalystsStrong Buy
Price Target15.00 (+155.97%)
Earnings DateNov 20, 2025

About HIND

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 18
Stock Exchange NASDAQ
Ticker Symbol HIND
Full Company Profile

Financial Performance

In 2024, Vyome Holdings's revenue was $256,944, a decrease of -38.23% compared to the previous year's $415,940. Losses were -$1.45 million, 81.0% more than in 2023.

Financial Statements

Analyst Summary

According to one analyst, the rating for HIND stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target
$15.0
(155.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Vyome Holdings Acquires MIT AI Spinout Oculo Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo,...

9 days ago - Business Wire

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the...

21 days ago - Business Wire

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technolog...

4 weeks ago - Business Wire

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced the interim results from its investigator-initiated Phase...

4 weeks ago - Business Wire

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an ...

6 weeks ago - Business Wire

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced its Board of Directors has agreed to conduct a ...

7 weeks ago - Business Wire

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets wit...

7 weeks ago - Business Wire

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with l...

Other symbols: RSLS
7 weeks ago - Business Wire

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large marke...

Other symbols: RSLS
2 months ago - Business Wire

Vyome Announces New Board of Directors with Deep MIT and AI Ties

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potentia...

Other symbols: RSLS
2 months ago - Business Wire

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced ...

Other symbols: RSLS
2 months ago - Business Wire

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved

Other symbols: RSLS
2 months ago - GlobeNewsWire

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025

Other symbols: RSLS
2 months ago - GlobeNewsWire

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Other symbols: RSLS
2 months ago - GlobeNewsWire

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Port...

Other symbols: RSLS
3 months ago - GlobeNewsWire

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 2...

Other symbols: RSLS
3 months ago - GlobeNewsWire

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025...

Other symbols: RSLS
3 months ago - GlobeNewsWire

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia

Other symbols: RSLS
3 months ago - GlobeNewsWire

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members Recon Supply Named Exclusive...

Other symbols: RSLS
4 months ago - GlobeNewsWire

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ®  (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, tod...

Other symbols: RSLS
4 months ago - GlobeNewsWire

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality ...

Other symbols: RSLS
4 months ago - GlobeNewsWire

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial result...

Other symbols: RSLS
5 months ago - GlobeNewsWire

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 700 points on Monday.

Other symbols: ORLARSLS
5 months ago - Benzinga

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board ...

Other symbols: RSLS
5 months ago - GlobeNewsWire

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation...

Other symbols: RSLS
5 months ago - GlobeNewsWire